Apply for Grants
The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Developing an Inhibitor of Transglutaminase 2 as a Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Clumping of alpha-synuclein in the brain is a key pathological feature of Parkinson’s disease (PD) and is believed to lead to brain cell degeneration. Identifying factors that...
-
Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2022Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells
Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...
-
Summer 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022Assessing Whether Cholesterol or Its Metabolites Increase the Risk of Developing Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) has been associated with a dysregulation of cholesterol metabolism in brain cells and the accumulation of a protein called alpha-synuclein. Our research is...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction
Study Rationale: Mitochondrial dysfunction in dopamine-producing neurons is one of the hallmarks of Parkinson’s disease (PD) pathology. Inside mitochondria is a protein called Paraoxonase 2 (PON2)...
-
Research Grant, 2022Development of a Safe and Efficient Method to Treat Parkinson’s Disease Using RNA-based Gene Therapy
Study Rationale: Gene mutations are one of several cause of Parkinson’s disease (PD). Developing an efficient method for introducing functional versions of these mutated genes into cells that are...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Examining the Action of Potassium Channels and the Inflammasome in a Signaling Axis That Can Serve as a Pharmacological Target Against Parkinson’s Disease
Study Rationale: Both voltage-gated potassium channels and inflammatory signaling are known to be involved in Parkinson’s disease (PD). Each of these signaling systems contributes to the brain...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.